Ralinepag shows delayed disease progression in PAH study

Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study also met several important secondary goals, including six-minute walk distance.

Gossamer announces topline results from Phase 3 seralutinib study

Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores.

Pulmovant completes Phase 2 study enrollment for PH-ILD drug

Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.

Cereno to expand drug development focus to PH-ILD

Cereno Scientific plans to focus development of its HDAC inhibitor CS014 on PH related to interstitial lung disease. The treatment targets key pathophysiological processes found in fibrotic lung disease and pulmonary vascular disease.